

the ability to proactively address potential medication-related issues, contributing to improved patient safety. From this point of view, access to the direct opinions and experiences of patients represents an added value of immeasurable wealth that requires the knowledge of a healthcare professional to interpret correctly.

Indeed, the risk of misuse of social media is linked to the rapid spread of potentially unverified information that has not been communicated by a professional. The boundary between informative content and promotional material blurs as influencers, often with substantial follower bases, endorse medications for uses not approved by regulatory authorities.

This seminar delves into the ethical considerations surrounding such endorsements, exploring the impact on patient perceptions, adherence, and the responsibilities of hospital pharmacists in mitigating potential risks.

ER2 - The second life of drugs: opportunities and challenges of drug repurposing

Drug repurposing, also known as drug repositioning or reprofiling, refers to the process of identifying new therapeutic uses for existing drugs that were initially developed for a different indication.

In this session, we will discuss the key principles underlying drug repurposing, emphasizing the shift from traditional de novo drug discovery to the exploration of existing compounds for new therapeutic indications. Attendees will gain insights into the diverse methodologies employed in identifying repurposable candidates, ranging from computational approaches and high-throughput screenings to systems biology analyses.

Drug repurposing can lead to the accelerated approval of treatments, saving both time and resources, compared to the conventional drug development pipeline. The potential of this approach for drug approval is particularly interesting in areas such as rare diseases. However, the road to drug repurposing is not without challenges. The session will address issues such as regulatory considerations, intellectual property hurdles, and the need for innovative clinical trial designs tailored to repurposed drugs. Ethical considerations surrounding patient safety and consent will also be explored, emphasizing the importance of striking a balance between speed and thorough evaluation.

Some ongoing initiatives at the European level from the research and regulatory perspective will be discussed so as to provide hospital pharmacists with basic understanding of the field's potential. By reimagining the applications of existing drugs, hospital pharmacists can play a pivotal role in expanding treatment options for unmet clinical needs.

ER3 - Update on the clinical trial landscape

For many years randomised controlled trials (RCTs) were deemed the gold standard for evidence-based medicine, mainly due to their ability to prevent bias through randomization. However, the landscape has changed, and RCTs are now facing challenges such as time constraints, high costs, and ethical barriers. To overcome such barriers, in recent years alternative clinical trial designs have emerged, each with its strengths and weaknesses.

Under the master protocol framework are grouped new clinical trial designs that investigate one or more than one treatment in multiple subgroups of a study population as opposed to the traditional RCTs, which mostly investigate one drug in one study population. The master protocol clinical trials include: basket trials, umbrella trials, and platform trials

This seminar will present the changing perspectives of clinical trial designs, comparing classical trial designs with newer trial designs and examining the role of the master protocols in the clinical trial landscape.

ER4 – Competency-based education – go for knowledge, skill and attitude!

As health care professionals, pharmacists require a solid education with a strong academic background. Yet, the fast changing and evolving pharmaceutical and medical knowledge necessitates a shift in training and education strategies. Competency-based education (CBE) has become a fundamental approach to medical education in numerous countries.

Competency-based curricula emphasize four key features: focus on learning outcomes, emphasis on abilities, reduced time-based training and learner-centeredness. The defined

learning outcomes describe the knowledge, skills and attitudes essential for a professional individual in working life. The design of a successful competency-based system of education begins with identifying desired outcomes and defining performance levels for each competency. This leads to the development of a framework for assessing competencies and finally the (re)evaluation of the programme, enabling continuous improvement.

Competency-based assessments are used to distinguish between the skills and knowledge that you already have, and those for which you need further education and training. The use of entrustable professional activities (EPAs) is an approach to deal with the complex nature of CBE. An EPA is a unit of professional practice that can be fully entrusted to a pharmacist as soon as he or she has demonstrated the necessary competence to execute this activity unsupervised.

EPAs can effectively bridge the gap between educational preparation and job practice, ensuring that pharmacists are equipped not only with knowledge but also with the skills and attitudes necessary for professional success.

This seminar will show examples of innovative approaches illustrating the practical implementation of CBE and EPAs in pharmacy education settings - at undergraduate, postgraduate, and professional development levels.

Two experienced speakers will share their experiences, best practices, and insights into successful implementation of CBE.

INT3 - Research is for everyone?

How can hospital pharmacists develop and improve hospital pharmacy services? What kind of impact do hospital pharmacists have on patient care? How can hospital pharmacists change health policy? Is research for everyone? The examples and experiences discussed in this session are highly transferable to other healthcare settings.

The first part of this session will focus on how hospital pharmacists can become involved in research and start research projects. Additionally, what kind of training or support is needed for research will be discussed. Examples of research projects will be shared, and their impact on hospital pharmacy services and patient care will be discussed.

The second part of this session will focus on how hospital pharmacists can involve stakeholders including but not limited to healthcare professionals and patients with their families, in research. Collaboration with other stakeholders enriches the quality and impact of the research. How pharmacists can build a research portfolio, or even a research centre, based on a shared vision? The impact of innovative research, education, and clinical initiatives on the care and medication therapy of aging adults and, ultimately, on health policy will be discussed.

PHARMACOTHERAPY

Pharmacotherapy session - Anticoagulation therapy in hospitals: let's ask the experts

Annually, millions of patients worldwide, who suffer from thromboembolic conditions, necessitate anticoagulation therapy. Despite the undeniable advantages of anticoagulants in reducing thromboembolic events, these medications can be responsible for adverse drug events in hospitalized patients.

Particularly anticoagulation management is more complex in those patients with comorbidities such as renal or liver impairment, or patients with specific characteristics such as high body weight, and frailty, patients with a high risk of bleeding or who have previously experienced bleeding events while on anticoagulants.

In this interactive session, our panel of experts will discuss the management of anticoagulation therapy in complex case scenarios and will answer questions on issues the attendees have encountered while managing their patients on anticoagulants or anticoagulant reversal agents.

YOUNG PROFESSIONALS

Young Professionals Session - A European perspective on hospital pharmacy training

This year's Young Professionals Session will be dedicated to the education and training required to become a hospital pharmacist.

While we all share the same profession and title, "hospital pharmacist" across Europe, the education and specializations required to achieve this differ. Pre-graduation education, post-graduation specialization, internships, residency, specific diplomas—training varies by country, though some

similarities exist between different European nations. In this session several hospital pharmacists will present their country's training programs for becoming a hospital pharmacist. They will explain how these programs enable them to practice high-quality pharmacy tailored to their diverse responsibilities, as well as discuss some of their negative aspects. This conference will provide a European and international perspective on hospital pharmacist training and offer insights for potential future harmonization of these educational paths.

Join the Young Professionals Session to be trained in hospital pharmacy across Europe!



2nd Announcement COPENHAGEN 2025



29TH EAHP CONGRESS 12-13-14 MARCH

PERSON CENTRED PHARMACY - NAVIGATING DIGITAL HEALTH

SCIENTIFIC COMMITTEE*

Chairman

Prof. Dr. Thomas De Rijdt (Belgium)

Members

Dr. Torsten Hoppe-Tichy (Germany)
Dr. Ulrika Gillespie (Sweden)
Mrs. Despoina Makridaki (Greece)
Dr. Gunar Stemer (Austria)
Dr. Inese Sviestīņa (Latvia)
Dr. Juraj Sykora (Slovakia)
Dr. Virginia Silvari (Ireland)
Mr. Jonathan Underhill (United Kingdom)
Mr. Armando Alcobia (Portugal)
Dr. Fatma Karapinar (The Netherlands)
Dr. Stefanie Deuster (Switzerland)
Dr. Daniele Mengato (Italy)
Dr. Xandra Garcia Gonzalez (Spain)
Dr. Clement Delage (France)
Mr. Adrin Dadkhah (Germany)
Mrs. Barbora Kostalova (Czech Republic)
Mrs. Chiara Lamesta (Italy)
Mrs. Hanna Tolonen (Finland)
Mrs. Joo Hanne Poulsen (Denmark)
Mrs. Roisin O'Hare (United Kingdom)
Mrs. Sandra Vezmar Kovasevic (Serbia)
Mrs. Sonja Guntschnig (Austria)

*EAHP confirms that Scientific Committee members responsible for the development of the Congress programme have signed and submitted the Conflict of Interest Disclosure forms

ORGANISING COMMITTEE

Dr. Nenad Miljković (Serbia) - President of the EAHP (Chairman)
Dr. András Süle (Hungary) - Immediate Past President of the EAHP
Louis Bertin (France) - Director of Finances of the EAHP
Prof. Dr. Thomas De Rijdt (Belgium) - Chairman of the Scientific Committee
Jennie De Greef (United States) - Managing Director

CONGRESS & EXHIBITION ORGANISERS

EAHP Congress Secretariat
EAHP Headquarters
European Association of Hospital Pharmacists (EAHP)
Boulevard Brand Whitlock 87 Box 11 (4th floor)
1200 Brussels, Belgium
Email registration: registration@eahp.eu
Email secretariat: congress@eahp.eu
Email exhibition: exhibition@eahp.eu
Website: www.eahp.eu

Official Congress Media

Ejhp Editorial Office Bmj Group
BMA House, Tavistock Square
WC1H 9JR London, United Kingdom
Tel: + 44 (020) 7387 4410
Website: www.bmj.com

CONGRESS VENUE

Bella Center Copenhagen
Center Blvd 9, Entrance 4, 2300 Copenhagen S

REGISTRATION

Registration Fee Student | 200 €
Registration Fee Young Professional | 350 €
Registration Fee Hospital pharmacy specialization resident student | 350 €
Registration Fee before 1 December 2024 | 546 €
Registration Fee beginning 1 December 2024 | 670 €
Registration Fee beginning 1 February 2025 | 765 €

Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday and Thursday and coffee/tea during official breaks.

The registration fee does not include VAT.
25% Danish VAT will be added at the end.

PAYMENT TERMS

Cheques will NOT be accepted. Only payments made in Euro will be accepted. As confirmation of registration, an invoice will be issued after receipt of the Registration form.

CANCELLATION POLICY

Cancellation of individual or group registrations received before 31 December 2024 will be refunded, less 100€ + 25% Danish VAT per registration/participant, in order to cover bank and administration charges.

For groups, a maximum of 15% of the registrations may be cancelled before 31 December 2024, less 100 € + 25% Danish VAT, per registration/participant, in order to cover bank and administration charges per participant). No refunds can be made after this date but substitution is always accepted.

All cancellations or changes must be sent in writing by the given deadline to registration@eahp.eu.

NOTE: PLEASE DO NOT SEND INDIVIDUAL REGISTRATION FORMS FOR GROUPS OF DELEGATES.

HOTEL ACCOMMODATION

MCI

Email: eahp.housing@wearemci.com

NOTE THAT ALL HOTEL BOOKINGS WILL BE MADE THROUGH THE EAHP WEBSITE VIA THE LINK TO THE HOUSING BUREAU.

All payments, changes and cancellations for hotel accommodations will be handled directly by the housing bureau.

Audio and Video presentations from the previous Congress are now available via the EAHP website
www.eahp.eu/publications/webcasts



The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

